Presynaptic and postsynaptic nigrostriatal dopaminergic functions in multiple system atrophy

NeuroReport

Volumn 19, Issue 2, 2008, Pages 145-150

  Hashimoto, Masaya ^a,b   Kawasaki, Keiichi ^a   Suzuki, Masahiko ^a,b   Mitani, Kazuko ^a,c   Murayama, Shigeo ^a   Mishina, Masahiro ^a,d   Oda, Keiichi ^a   Kimura, Yuichi ^a   Ishiwata, Kiichi ^a   Ishii, Kenji ^a   Inoue, Kiyoharu ^b  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

^d NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Dopamine receptor; Dopamine transporter; L 3,4,dihydroxyphenyl alanine responsiveness; Multiple system atrophy; Parkinson; Positron emission tomography

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; RACLOPRIDE C 11;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SHY DRAGER SYNDROME; TREATMENT RESPONSE;

AGED; BIOLOGICAL MARKERS; CORPUS STRIATUM; DENDRITES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEURAL PATHWAYS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PRESYNAPTIC TERMINALS; RECEPTORS, DOPAMINE D2; SUBSTANTIA NIGRA; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 38049108188     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3282f3e3d8     Document Type: Article

References (24)

1. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neuro Neurosurg Psychiatry 1995; 58:160-166.
2. James SL, Nigel L. Disorders of movement and system degeneration. In: David IG, Peter LL, editors. Greenfield's Neuropathology. 7th ed. Vol. 2. London: Arnold; 2002. pp. 325-430.
3. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73:517-523.
4. 123I-IBZM single photon emission computed tomography. Arch Neurol 1993; 50:513-516.
5. Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. 'Minimal change' multiple system atrophy. Mov Disord 1994; 9:161-166.
6. Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998; 8:359-362.
7. Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang GJ, Ding YS, et al. PET evaluation of the dopamine system of human brain. J Nucl Med 1996; 37:1242-1256.
8. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26:171-182.
9. 11C]CFT binding to the striatal dopamine transporters in the Fischer 344 rats: a PET study. Ann Nucl Med 2003; 17:249-253.
10. 11C]methyl triflate. J Labelled Comp Radiopharm 1999; 42:1183-1193.
11. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. Ann Nucl Med 1997; 11:307-313.
12. Ardekani BA, Braun M, Hutton BF, Kanno I, Iida H. A fully automatic multimodality image registration algorithm. J Comput Assist Tomogr 1995; 19:615-623.
13. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 1997; 6:279-287.
14. 11C]WIN 35 428. Synapse 1993; 15:130-142.
15. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34:423-431.
16. 11C-raclopride. Arch Neurol 1993; 50:474-480.
17. Mozley PD, Stubbs JB, Kung HF, Selikson MH, Stabin MG, Alavi A. Biodistribution and dosimetry of iodine-123-IBF: a potent radiolig and for imaging the D2 dopamine receptor. J Nucl Med 1993; 34:1910-1917.
18. Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ann Neurol 1999; 46:723-731.
19. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94:79-100.
20. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998; 44:415-422.
21. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998; 249:180-182.
22. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34:324-330.
23. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990; 13:553-558.
24. 2 receptors. Ann Neurol 1993; 34:219-226.